LLY
Eli Lilly and Company
LLY has the edge over NRIX overall, supported by lower modeled downside and stronger valuation.
NRIX
Nurix Therapeutics, Inc.
NRIX offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NRIX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NRIX's revenue, profitability, cash flow and balance sheet are all currently strong.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NRIX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.7x | $15.49 | -0.7% |
| Current | 6.8x | $15.60 | — |
| Fair | 11x | $24.25 | +55% |
| Expensive | 11x | $25.81 | +65% |
Historical ranges are pointers, not guarantees.
NRIX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NRIX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NRIX's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NRIX on earnings, with more consistent year-over-year improvement.
NRIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.30 | +$5.26 |
| Q2 2026 | -$3.46 | -$0.86 |
| Q1 2026 | -$3.17 | -$0.38 |
| Q4 2025 | -$3.05 | -$0.17 |
| Q3 2025 | -$2.96 | -$0.05 |
| Q2 2025 | -$2.60 | +$0.32 |
| Q1 2025 | -$2.79 | -$0.13 |
| Q4 2024 | -$2.88 | -$0.23 |
NRIX has returned to profit: it earned $2.30 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NRIX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
NRIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $673.1M | +8426% |
| Q2 2026 | $9M | -79% |
| Q1 2026 | $6.3M | -66% |
| Q4 2025 | $13.6M | +2.2% |
| Q3 2025 | $7.9M | -37% |
| Q2 2025 | $44.1M | +264% |
| Q1 2025 | $18.5M | +11% |
| Q4 2024 | $13.3M | -12% |
NRIX's revenue is growing: $673M last quarter, up 8426% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 83% | +1241 points |
| Q2 2026 | -1042% | -932 points |
| Q1 2026 | -1479% | -1139 points |
| Q4 2025 | -612% | -125 points |
| Q3 2025 | -1158% | -724 points |
| Q2 2025 | -110% | +292 points |
| Q1 2025 | -341% | -68 points |
| Q4 2024 | -487% | -188 points |
NRIX has the edge over LLY on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NRIX on cash flow, with more consistent year-over-year improvement.
NRIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $614.2M | +$674.3M |
| Q2 2026 | -$98.5M | -$32.7M |
| Q1 2026 | -$73M | -$8.4M |
| Q4 2025 | -$73M | -$22.1M |
| Q3 2025 | -$60.1M | -$15.6M |
| Q2 2025 | -$65.8M | -$24.2M |
| Q1 2025 | -$64.6M | -$19.7M |
| Q4 2024 | -$50.9M | -311% |
NRIX's free cash flow has turned positive after six years mostly in the red: $370M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NRIX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NRIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.6% | +5.1M shares |
| 1 year | +38% | +32M shares |
| 3 years | +114% | +61.8M shares |
| 5 years | +162% | +71.8M shares |
| Available history | +459% | +95.4M shares |
NRIX has 116M diluted shares, up 38% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | $1,000 |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NRIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.4x | Net Cash |
NRIX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NRIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 29.8 | Neutral |
NRIX's weekly RSI is 36 (neutral) and its Stochastic is 30 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NRIX PE vs Healthcare Sector
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NRIX on trend strength, trading above more of its moving averages.
NRIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.0 | 29% below |
| 20 week MA | $23.7 | 34% below |
| 50 week MA | $19.7 | 21% below |
| 100 week MA | $16.3 | 4.4% below |
| 200 week MA | $14.9 | 4.5% above |
NRIX has fallen below most of its moving averages, though it's still 4.5% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NRIX on returns for 2026, with the stronger performance.
NRIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.0 | $43.8 | +131% |
| 2021 | $43.8 | $30.5 | -30% |
| 2022 | $30.5 | $10.4 | -66% |
| 2023 | $10.4 | $10.3 | -0.6% |
| 2024 | $10.3 | $19.1 | +85% |
| 2025 | $19.1 | $19.3 | +1% |
| 2026 YTD | $19.3 | $15.6 | -19% |
NRIX's yearly returns have swung widely, from +131% in 2020 to −66% in 2022. It's down 19% so far in 2026.